



Tatva Chintan Pharma Chem Limited
(Formerly known as Tatva Chintan Pharma Chem Private Limited)
(CIN:L24232GJ1996PLC029894)



Date: 25 January 2023

Ref. No.: TCPCL/SEC/2022-23/00093

To,
The General Manager,
Corporate relationship department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001
Scrip Code: 543321

The Manager,
Listing department,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G,
Bandra-Kurla, Complex Bandra(E),
Mumbai-400 051
Scrip Symbol: TATVA

Subject: Newspaper Publication of extract of financial results of the Company

Dear Sir/Madam,

Pursuant to regulation 30 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we are enclosing herewith copies of newspaper publication of extract of financial results of the Company for the quarter and nine months ended 31 December 2022, published in Financial Express (English edition) and Vadodara Samachar (Gujarati edition) on 25 January 2023.

The above information shall be made available on the website of the Company at www.tatvachintan.com.

Kindly take the same on record and disseminate to the public at large.

Thanking You,

Your Faithfully,
For Tatva Chintan Pharma Chem Limited

Ishwar Nayi
Company Secretary and Compliance Officer
M. No.: A37444

Encl.: As above

| Sr. No. | | Quarter ended | | Nine months ended | | Year ended | |
|---------|--|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|-------------------------|
| | | 31.12.2022 (Unaudited) | 30.09.2022 (Unaudited) | 31.12.2021 (Unaudited) | 31.12.2022 (Unaudited) | 31.12.2021 (Unaudited) | 31.03.2022 (Audited) |
| 1. | Total income from operations | 1,206.07 | 900.91 | 1,046.70 | 2,991.00 | 3,351.17 | 4,336.47 |
| 2. | Net profit / (loss) for the period (before tax, exceptional and/or extraordinary items) | 142.23 | 90.58 | 254.68 | 369.73 | 851.45 | 1,041.21 |
| 3. | Net profit / (loss) for the period before tax (after exceptional and/or extraordinary items) | 142.23 | 90.58 | 254.68 | 369.73 | 851.45 | 1,041.21 |
| 4. | Net profit / (loss) for the period after tax (after exceptional and/or extraordinary items) | 116.23 | 71.12 | 228.07 | 285.28 | 783.64 | 958.74 |
| 5. | Total comprehensive income for the period [comprising profit / (loss) for the period (after tax) and other comprehensive income (after tax)] | 117.82 | 73.76 | 227.72 | 290.54 | 782.29 | 960.27 |
| 6. | Equity share capital | 221.65 | 221.65 | 221.65 | 221.65 | 221.65 | 221.65 |
| 7. | Reserves (excluding revaluation reserve) as shown in the audited balance sheet of the previous year | | | | | | 4,509.24 |
| 8. | Earnings per share (of Rs. 10/- each) (not annualised) | | | | | | |
| | - Basic: | 5.24 | 3.21 | 10.29 | 12.87 | 36.82 | 44.59 |
| | - Diluted: | 5.24 | 3.21 | 10.29 | 12.87 | 36.82 | 44.59 |

(Currency: Indian Rupees in Million, except per share data)

EXTRACT OF CONSOLIDATED STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2022

| Sr. No. | | Quarter ended | | Nine months ended | | Year ended | |
|---------|------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|-------------------------|
| | | 31.12.2022 (Unaudited) | 30.09.2022 (Unaudited) | 31.12.2021 (Unaudited) | 31.12.2022 (Unaudited) | 31.12.2021 (Unaudited) | 31.03.2022 (Audited) |
| 1. | Total income from operations | 1,135.37 | 840.38 | 1,015.92 | 2,836.39 | 3,259.31 | 4,278.11 |
| 2. | Net profit before tax | 131.53 | 68.14 | 247.75 | 319.41 | 833.05 | 1,032.66 |
| 3. | Net profit after tax | 105.57 | 52.56 | 224.28 | 243.12 | 771.01 | 959.87 |
| 4. | Total comprehensive income | 104.71 | 52.13 | 224.70 | 241.40 | 769.89 | 958.42 |

(Currency: Indian Rupees in Million)

KEY NUMBERS OF STANDALONE STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2022

Notes:

- The Consolidated & Standalone Financial Results for the quarter and nine months ended 31 December 2022, were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 24 January 2023, which have been subjected to limited review by the statutory auditors of the Company, who has expressed unmodified opinion.
- The above is an extract of the detailed format of Financial Results for the quarter and nine months ended 31 December 2022, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The full format of Financial Results for the quarter and nine months ended 31 December 2022, are available on the websites of the Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively and also on the Company's website at www.tatvachintan.com.
- Figures for the previous periods/year have been re-classified / re-arranged / re-grouped to conform to classification of current period, wherever necessary.

**For and on behalf of the Board of Directors of
Tatva Chintan Pharma Chem Limited**
Sd/-
Chintan N. Shah
Chairman and Managing Director
DIN: 00183618

Place : Vadodara, Gujarat, India.
Date : 24 January 2023



TATVA CHINTAN PHARMA CHEM LIMITED

(Formerly known as Tatva Chintan Pharma Chem Private Limited)

CIN: L24232GJ1996PLC029894

Registered Office : Plot No. 502 / 17, GIDC Estate, Ankleshwar, Dist. Bharuch, Gujarat - 393 002

Website : www.tatvachintan.com E-mail : cs@tatvachintan.com Tel. No. : +91 75748 48533

EXTRACT OF CONSOLIDATED STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2022

(Currency: Indian Rupees in Million, except per share data)

| Sr. No. | Particulars | Quarter ended | | | Nine months ended | | Year ended |
|---------|--|---------------|-------------|-------------|-------------------|-------------|------------|
| | | 31.12.2022 | 30.09.2022 | 31.12.2021 | 31.12.2022 | 31.12.2021 | 31.03.2022 |
| | | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| 1. | Total income from operations | 1,206.07 | 900.91 | 1,046.70 | 2,991.00 | 3,351.17 | 4,336.47 |
| 2. | Net profit / (loss) for the period (before tax, exceptional and/or extraordinary items) | 142.23 | 90.58 | 254.68 | 369.73 | 851.45 | 1,041.21 |
| 3. | Net profit / (loss) for the period before tax (after exceptional and/or extraordinary items) | 142.23 | 90.58 | 254.68 | 369.73 | 851.45 | 1,041.21 |
| 4. | Net profit / (loss) for the period after tax (after exceptional and/or extraordinary items) | 116.23 | 71.12 | 228.07 | 285.28 | 783.64 | 958.74 |
| 5. | Total comprehensive income for the period [comprising profit / (loss) for the period (after tax) and other comprehensive income (after tax)] | 117.82 | 73.76 | 227.72 | 290.54 | 782.29 | 960.27 |
| 6. | Equity share capital | 221.65 | 221.65 | 221.65 | 221.65 | 221.65 | 221.65 |
| 7. | Reserves (excluding revaluation reserve) as shown in the audited balance sheet of the previous year | | | | | | 4,509.24 |
| 8. | Earnings per share (of Rs. 10/- each) (not annualised) | | | | | | |
| | - Basic: | 5.24 | 3.21 | 10.29 | 12.87 | 36.82 | 44.59 |
| | - Diluted: | 5.24 | 3.21 | 10.29 | 12.87 | 36.82 | 44.59 |

KEY NUMBERS OF STANDALONE STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2022

(Currency: Indian Rupees in Million)

| Sr. No. | Particulars | Quarter ended | | | Nine months ended | | Year ended |
|---------|------------------------------|---------------|-------------|-------------|-------------------|-------------|------------|
| | | 31.12.2022 | 30.09.2022 | 31.12.2021 | 31.12.2022 | 31.12.2021 | 31.03.2022 |
| | | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| 1. | Total income from operations | 1,135.37 | 840.38 | 1,015.92 | 2,836.39 | 3,259.31 | 4,278.11 |
| 2. | Net profit before tax | 131.53 | 68.14 | 247.75 | 319.41 | 833.05 | 1,032.66 |
| 3. | Net profit after tax | 105.57 | 52.56 | 224.28 | 243.12 | 771.01 | 959.87 |
| 4. | Total comprehensive income | 104.71 | 52.13 | 224.70 | 241.40 | 769.89 | 958.42 |

Notes:

- The Consolidated & Standalone Financial Results for the quarter and nine months ended 31 December 2022, were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 24 January 2023, which have been subjected to limited review by the statutory auditors of the Company, who has expressed unmodified opinion.
- The above is an extract of the detailed format of Financial Results for the quarter and nine months ended 31 December 2022, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The full format of Financial Results for the quarter and nine months ended 31 December 2022, are available on the websites of the Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively and also on the Company's website at www.tatvachintan.com.
- Figures for the previous periods/year have been re-classified / re-arranged / re-grouped to conform to classification of current period, wherever necessary.

**For and on behalf of the Board of Directors of
Tatva Chintan Pharma Chem Limited**

Sd/-

Chintan N. Shah

Chairman and Managing Director

DIN: 00183618

Place : Vadodara, Gujarat, India.

Date : 24 January 2023